JUNS - Rasio kapitalisasi pasar marang pendapatan Jupiter Neurosciences
Jupiter Neurosciences Inc faces logistical risks and patent protection complexities driven by geopolitics. However, a unique method of delivering substances to the brain ensures high business scalability. The current success of management depends directly on clinical test results. The price-to-sales ratio reflects market expectations, with the parameter reaching 41.20, which determines the asset's current valuation.
Rincian metrik lan analitis perusahaan Jupiter Neurosciences Inc (JUNS)
- rega saham lan konsensus proyeksi valuasi:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Jupiter Neurosciences Inc|JUNS - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal jupiterneurosciences.com|JUNS - Utang perusahaan|Utang-utang marang nilai buku Jupiter Neurosciences|JUNS - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Jupiter Neurosciences|Indikator likuiditas cepet jupiterneurosciences.com
- indikator pendapatan resik lan kelipatan nilai:
JUNS - Bathi resik|Prakiraan bathi perusahaan Jupiter Neurosciences Inc|JUNS - Pangali P/E|Rasio prakiraan rega marang bathi Jupiter Neurosciences, Inc.|JUNS - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Jupiter Neurosciences|JUNS - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Jupiter Neurosciences|JUNS - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan jupiterneurosciences.com|JUNS - Wutah bathi saben saham ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Jupiter Neurosciences Inc
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:JUNS - Jupiter Neurosciences, Inc.
The stability of raw material supplies for neurotherapy at Jupiter Neurosciences Inc. (JUNS) establishes a foundation for assessing the business's real value by comparing market demand with revenue volumes. The price-to-sales ratio, reflected in the P/S valuation, allows investors to filter out speculative noise from fundamental growth. This metric measures how much investors are willing to pay per unit of generated revenue. Analyzing the curve helps balance potential profits against the risk of a prolonged drawdown.
Pesaing Jupiter Neurosciences Inc
BIIB (biogen.com) - Rasio kapitalisasi pasar marang pendapatan|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RGC|AXSM - Rasio rega marang pendapatan|ACAD (ACADIA Corp) - Rasio kapitalisasi marang pendapatan|XENE: Multiplikator P/S|Rega marang dodolan vikingtherapeutics.com (VKTX)|Kapitalisasi marang pendapatan SUPN|Multiplikator P/S Catalyst Pharma|Rasio rega marang pendapatan Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Biohaven Ltd. BHVN|amylyx.com (AMLX) - Rega marang dodolan|TRVI - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Praxis Precision Medicines Inc PRAX|AVXL: Multiplikator P/S|Kapitalisasi marang pendapatan CeriBell EEG|PRTA (Prothena Biosciences) - Multiplikator P/S|Alector Therapeutics (ALEC) - Koefisien rega marang pendapatan|Multiplikator P/S ANNX|OMER - Rega marang dodolan|Rasio rega marang pendapatan Neurogene Corp NGNE|ACIU: Rasio kapitalisasi marang pendapatan|Voyager Therapeutics - Multiplikator P/S|neumoratx.com (NMRA) - Kapitalisasi marang pendapatan|SCLX: Multiplikator P/S|Rega marang dodolan Tevogen Bio Holdings Inc. (TVGN)|Rasio rega marang pendapatan Alpha Cognition Inc|Cognition Therapeutics Inc. (CGTX) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan IKT (Inhibikase Therapeutics)|SAVA (cassavasciences.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ASRT (Assertio)|Koefisien rega marang pendapatan Coya Therapeutics Inc (COYA)|VTGN - Rasio rega marang pendapatan|OVID (Ovid Therapeutics Inc.) - Rasio kapitalisasi marang pendapatan|ABOS: Multiplikator P/S|Kapitalisasi marang pendapatan cervomed.com|Rasio rega marang pendapatan Alterity Therapeutics Ltd.|CLNN (Clene Nanomedicine) - Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan PEPG (PepGen Inc.)|Multiplikator P/S Relmada Corp (RLMD)|Rasio rega marang pendapatan Annovis Bio, Inc. ANVS|GRCE: Rasio kapitalisasi marang pendapatan|AIFF - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Klotho Neurosciences Inc KLTO|neurosense-tx.com (NRSN) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan RVPH|MTVA (MetaVia Inc.) - Multiplikator P/S|Rega marang dodolan neuraxis.com NRXS|Kapitalisasi marang pendapatan HSDT (Helius Medical)|Multiplikator P/S passagebio.com (PASG)|Rasio rega marang pendapatan Neuphoria Therapeutics NEUP|Rasio kapitalisasi pasar marang pendapatan NERV|ATHA - Rasio rega marang pendapatan|Rega marang dodolan addextherapeutics.com|alzamend.com (ALZN) - Rasio rega marang pendapatan|CYCN: Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan PTIX|Multiplikator P/S Pasithea|Rasio rega marang pendapatan Cortigent, Inc. (CRGT)|ATXI: Rasio rega marang dodolan|Multiplikator P/S BCLI (BrainStorm Cell Therapeutics)|Koefisien rega marang pendapatan Cara Therapeutics Inc. (CARA)|CHRO: Kapitalisasi marang pendapatan|Eliem Therapeutics - Kapitalisasi marang volume dodolan|ITCI: Multiplikator P/S|Rega marang dodolan longboardpharma.com (LBPH)|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan NRBO (NeuroBo)|SAGE (Sage Therapeutics Inc) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|TRVN: Rasio kapitalisasi marang pendapatan|Vigil Neuro - Multiplikator P/S|Rega marang dodolan anewmeds.com|CERE (Cerevel) - Kapitalisasi marang pendapatan
